The inwardly rectifying potassium (Kir) channel subunit Kir4.1 is specifically expressed in brain astrocytes and Kir4.1-containing channels (Kir4.1 channels) mediate astroglial spatial potassium (K + ) buffering. Recent advances in Kir4.1 research revealed that Kir4.1 channels can serve as a novel therapeutic target for epilepsy. Specifically, reduced expression or dysfunction of Kir4.1 channels seems to be involved in generation of generalized tonic-clonic seizures (GTCS) in animal models of epilepsy and patients with temporal lobe epilepsy. In addition, recent clinical studies showed that loss-of-function mutations of human gene (KCNJ10) encoding Kir4.1 elicit "EAST" or "SeSAME" syndrome which manifests as GTCS and ataxia. Although the precise mechanisms remain to be clarified, it is suggested that dysfunction of Kir4.1 channels disrupts spatial K + buffering by astrocytes, elevates extracellular levels of K + and/or glutamate and causes abnormal excitation of neurons in the limbic regions and neocortex. All these findings suggest that agents that activate or up-regulate astroglial Kir4.1 channels would be effective for epilepsy. In addition, docking simulation analysis using the Kir4.1 homology model provides important information for designing new Kir4.1 ligands. Discovery of such agents that activate or up-regulate Kir4.1 channels would be a novel approach for the treatment of epilepsy.
Introduction
Epilepsy is a serious neurological disorder that is clinically characterized by recurrent spontaneous seizures attributed to abnormal excitation of the brain [1, 2] . Epilepsy can be classified as generalized seizures (e.g., generalized tonic-clonic, absence and myoclonic seizures) and partial seizures (e.g., simple and complex focal seizures), depending on the epileptic foci involved. Various antiepileptic agents are available to treat epilepsy and the action mechanisms include the blockade of voltage-dependent sodium channels (e.g., sodium valproate, phenytoin, carbamazepine and lamotrigine), the activation of GABAergic neurotransmissionby inhibition of GABA transaminase (e.g., sodium valproate) or stimulation of GABA A receptors (e.g., phenobarbital and diazepam), the blockade of voltage-dependent calcium channels (e.g., gabapentin, lamotrigine and ethosuximide), or the antagonism of glutamate receptors (e.g., topiramate) [3] . However, these antiepileptic drugs often cause serious side effects (e.g., sedation, dizziness, Stevens-Johnson syndrome, toxic epidermal necrolysis and teratogenesis) and nearly one-third of patients with epilepsy are resistant to the current medications. Thus, there are strong clinical needs for the development of new medications or treatments for epilepsy.
Brain neurotransmission is mediated by tripartite synapses which consist of not only neural (i.e., pre-synaptic terminals
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and post-synaptic neurons), but also glial components (i.e., foot processes of astrocytes), implying that astrocytes play an important role in regulating neuronal activity [4, 5] . In fact, one astrocyte connects 10 5 synapses and, when stimulated by depolarization or certain receptors (e.g., mGluR2), astrocytes activate intracellular calcium signaling and release various neuroactive substances (e.g., glutamate, D-serine, ATP, cytokines and neurotrophic factors) [4, 5] . In addition, astrocytes play a key role in controlling environmental ion concentrations. Specifically, spatial potassium (K + ) buffering by astrocytes, which regulates extracellular K + ([K + ] o ) and glutamate ([Glu] o ) concentrations, directly affects neural excitability and is implicated in the pathogenesis and treatment of epilepsy [6] [7] [8] [9] . Furthermore, it is now known that spatial K + buffering is primarily mediated by inwardly rectifying potassium (Kir) channels comprising the Kir4.1 subunit which is highly expressed in astrocytes [7, 8] .
In this article, we review the pathophysiological role of astroglial spatial K + buffering and Kir4.1 channels in epileptic disorders and discuss their potential as a novel therapeutic target for epilepsy.
Spatial K + buffering and Kir4.1 channels in astrocytes
Astrocytes are the major glial cells contributing to a number of brain functions. Astrocytes form the blood-brain barrier with capillary blood vessels, maintain water and ion homeostasis, metabolize neurotransmitters, and excrete neuroactive molecules (e.g., glutamate, D-Serine, ATP, [4, 5, 7, 8] . Specifically, spatial K + buffering by astrocytes is critical in controlling the neural excitability. This system removes excess extracellular K + caused by neural repolarization at synapses and transports it uni-directionally to the regions of low K + such as capillary vessels [6] [7] [8] [9] (Fig. 1 ). In addition, spatial K + buffering is known to be coupled to extracellular glutamate uptake and water transport by astrocytes [10] [11] [12] . Thus, dysfunction of spatial K + buffering is assumed to cause neural hyperactivity by elevating extracellular K + and/or glutamate concentrations, consequently leading to seizure induction and/or spreading depression.
Kir channels are composed of 4 subunits, which are classified into seven families (Kir1.x through Kir7.x) encompassing more than fifteen members [13] . Among them, Kir4.1 subunits are highly expressed in brain astrocytes and retinal Müller cells, where they conduct K + buffering currents [14] [15] [16] [17] . It is now known that two types of Kir4.1-containing Kir channels (Kir4.1 channels) in astrocytes, the homo-tetramer of Kir4.1 and the hetero-tetramer of Kir4.1 and Kir5.1, conduct large inward K + currents at potentials negative to the K + equilibrium potential (E K ) (Fig. 2 ) [18, 19] . Therefore, depending on the difference between local E K and the membrane potential of astrocytes, they absorb excessive extracellular K + locally elevated at synapses and transport it to sites with low K + concentrations [7] [8] [9] 18] . Since spatial K + buffering is linked to glutamate uptake by astrocytes [10] [11] [12] [20, 21] .
Structure and drug interaction of Kir4.1 channels
Kir4.1 subunit consists of 379 amino acids with 2 transmembrane (TM)-spanning structures and forms Kir4.1 channels (homo-tetramer of Kir4.1 and hetero-tetramer of Kir4.1 and Kir5.1), which conduct large inward and relatively small outward K + currents ( Fig. 2 ) [22] . Among central nervous system (CNS) drugs, tricyclic antidepressants (TCAs, e.g., amitriptyline, nortriptyline, desipramine and imipramine) potently blocked Kir4.1 channels in a voltage-dependent manner (Fig. 3 ) [23, 24] . In addition, several selective serotonin reuptake inhibitors also inhibited Kir4.1 channels, but in a voltage-independent manner [25] . The inhibitory concentrations of antidepressants for Kir4.1 channels were considered to be within a range of clinical brain concentrations during the treatment of patients with depression. It is therefore likely that TCAs attenuate the spatial K + buffering functions of astrocytes by inhibiting Kir4.1 channels at clinical settings, which may explain some pharmacological actions such as their pro-convulsive action.
Mutational and in silico analysis of the drug interaction revealed that Kir4.1 channels have a pocket which specifically interacts with the antidepressants in the central cavity of the channel pore [26] . Specifically, Thr128 and Glu158 located in the Kir4.1 channel pore were identified to bind to the antidepressant molecules (Fig. 4) . Thus, Glu158 can interact with the amine moiety of the antidepressants with an ionic bond, while Thr128 can interact with the benzene ring (hydrogen bond acceptor) of TCA (i.e., nortriptyline) with a hydrogen bond. In addition, the volumes of the channel's central cavity in closed and open conformations were 220 Å 3 and 360 Å 3 , respectively, which could accommodate TCA (e.g., nortriptyline: 196 Å 3 ). This information on the structure and drug interaction of Kir4.1 channels is important to design new compounds not only for treating epilepsy (activation of Kir4.1 channels), but also for reducing pro-convulsive potential of new compounds (elimination of Kir4.1 channel affinity).
Pathophysiological alterations to Kir4.1 channels in epilepsy models Kir4.1-knockout mice showed no apparent pathological behaviors at birth [27] . However, Kir4.1 deletion in mice reduced body weight gain and led to progressive weakness and smaller body size by postnatal day (P) 8-10 (Table 1) . Thereafter, these animals exhibited severe and progressive defects in controlling voluntary movements, posture and balance, and consequently died prematurely (100% mortality at P24). Subsequent studies by Djukic et al. (2007) [21] using conditional knockout (cKO) techniques targeted to astroglial Kir4.1 demonstrated a clear linkage between dysfunction of astroglial K + buffering and induction of epileptic seizures (Table 1) . These animals developed pronounced body tremor, ataxia and evoked generalized tonic-clonic seizures (GTCS) with external stimuli (i.e., sudden touch). In addition, previous studies showed that brain Kir4.1 expression was significantly reduced in animal models of GTCS such as DBA/2 mice [28, 29] and Noda epileptic rats (NER) [30] . These findings indicate that dysfunction of Kir4.1 channels evokes convulsive seizures probably by disrupting K + buffering function of astrocytes.
Although information on the mechanisms of Kir4.1 channels underlying the control of seizure induction is very limited, NER, a hereditary animal model of GTCS [31] [32] [33] [34] [35] , showed a region-specific reduction in the Kir4.1 channel expression in the amygdala [30] (Table 1) . While no mutational changes in the Kir4.1-coding gene (Kcnj10) were observed in NER, Western blot analysis of the samples obtained under interictal conditions revealed that the expressional level of Kir4.1 (but not Kir5.1 or Kir2.1) was selectively diminished in the occipito-temporal cortex and thalamus among 10 brain regions examined (e.g., frontal, parieto-temporal and occipito-temporal cortex, hippocampus, striatum, thalamus, hypothalamus, midbrain, pons-medulla oblongata and cerebellum). Further immunohistochemical analysis of the occipito-temporal cortex showed a region-specific decrease in Kir4.1 channels in the amygdala, the medial amygdaloid nucleus and the basomedial amygdaloid nucleus, both structures being closely related to epileptogenesis and/or human epileptic disorders (e.g., temporal lobe epilepsy (TLE)) [36, 37] . In fact, a region-specific activation of amygdala neurons was confirmed in NER by the expression analysis of Fos protein, a biological marker of neural excitation. Interestingly, NER showed a specific loss of Kir4.1 channels in the perisynaptic astroglial processes surrounding the amygdaloid neurons without changes in the expressional level of Kir4.1 in the astroglial somata. These facts imply that the reduced expression (down-regulation)-induced dysfunction of Kir4.1 channels impairs astroglial K + buffering and causes hyperexcitation of amygdaloid neurons, leading to generation of GTCS (Fig. 5 ). This is supported by the findings that knockdown of Kir4.1 expression by siRNA or cKO of astroglial Kir4.1 impairs K + -and glutamate-uptake into astrocytes and causes neural excitation [20, 21] . In addition, seizure-susceptible DBA/2 mice carrying the T262A mutation in the Kcnj10 gene showed impaired Kir4.1 channel activity and glutamate clearance by astrocytes in the hippocampus [28, 29] . Furthermore, other animal models of epilepsy (e.g., a post-traumatic epilepsy model and an albumin-induced seizure model) also exhibited down-regulation of Kir4.1 expression in the neocortex or the hippocampus, illustrating the causative role of Kir4.1 channels in epileptogenesis (Fig. 5 ) [38, 39] . Status epilepticus (SE) via electrical or pharmacological (e.g., pilocarpine) stimulation produces neuronal damage in the limbic regions (e.g., hippocampus and amygdala), progressively increases seizure susceptibility of animals and consequently elicits spontaneous GTCS after several weeks. These characteristics are similar to those of human TLE featuring 1) localization of seizure foci in the limbic structures (e.g., hippocampus and amygdala), 2) existence of a "latent period", a seizure-free time interval following the initial precipitating injury, 3) incidence of mesial sclerosis leading to atrophy (e.g., neuronal loss and gliosis) in the limbic structures [40] [41] [42] [43] [44] . In the SE-induced TLE model, Kir4.1 expression was reduced in the temporal cortex shortly after SE [45] (Table 1) . Then, the down-regulated expression of Kir4.1 returned to the control level 1 week after SE. It was also shown that the expression of Kir4.1 was up-regulated 7-8 weeks after SE in the cerebral cortex, striatum and hypothalamus [46] . Immunohistochemical analysis illustrated that Kir4.1-immunoreactivity-positive astrocytes were increased in the above brain regions concomitantly with an increase in the total number of astrocytes (astrogliosis). In particular, Kir4.1 expression relative to the number of astrocytes (Kir4.1-positive cells/GFAP-positive cells ratio) was region-specifically elevated in the amygdala. These findings suggest that astroglial Kir4.1 channels in the amygdala play a role in modifying TLE epileptogenesis, probably by functioning as both causative (early phase) and inhibitory compensatory (late phase with spontaneous GTCS) mechanisms.
Finally, in contrast to the above described animal models with convulsive seizures, no expressional alterations to Kir4.1 were observed in Groggy rats, an animal model of absence seizures [47] (Table 1) . These results suggest a distinct role of Kir4.1 channels and spatial K + buffering in modulating convulsive seizures (e.g., GTCS and TLE seizures) vs. non-convulsive absence seizures.
Kir4.1 channels and human epileptic disorders
Evidence is accumulating that dysfunction of astroglial Kir4.1 channels cause epileptic seizures in humans. Specifically, loss-of-function mutations in the human gene KCNJ10 encoding Kir4.1 cause the epileptic disorders known as "EAST" (Epilepsy, Ataxia, Sensorineural deafness and Tubulopathy) or "SeSAME" (Seizures, Sensorineural deafness, Ataxia, Mental retardation, and Electrolyte imbalance) syndrome [48, 49] . "EAST" and "SeSAME" syndromes were reported independently by different groups, but consist mostly of identical symptoms: GTCS, ataxia, hearing loss and abnormal excretion of electrolytes ( Table 2) . The most frequent mutation of KCNJ10 was R65P at the cytoplasmic end of the first transmembrane region (TM-1) and others include G77R (TM-1), C140R (extracellular loop between TM-1 and TM-2), T164I, A167V (cytoplasmic end of TM-2), R175Q, R199X and R297C (C-terminal domain) [50] [51] [52] . All these Kir4.1 mutations caused drastic decreases in K + buffering currents conducted not only by Kir4.1 channels, but also by Kir4.1/5.1 channels. The hearing loss and abnormal renal excretion of electrolytes in the "EAST" or "SeSAME" syndrome seem to be attributable to Kir4.1 dysfunctions in the inner ear and the renal epithelial cells since Kir4.1 channels play crucial roles in maintaining endocochlear potential and transporting electrolytes in the scala media and the distal convoluted tubule, respectively [48, 49] .
Several single nucleotide polymorphisms (SNPs) of KCNJ10 have been shown to be associated with TLE accompanying febrile seizures [53] . In addition, clinical studies showed the down-regulation and/or impaired functioning of Kir4.1 channels in specimens from patients with TLE [54] [55] [56] , suggesting the involvement of Kir4.1 channels in TLE epileptogenesis.
Kir4.1 channels as a novel therapeutic target for epilepsy
Based on the evidence from animal and human studies, it is very likely that astroglial Kir4.1 channels play a crucial role in maintaining the spatial K + buffering function of astrocytes and that functional impairment or down-regulation of Kir4.1 channels evokes epileptic disorders (e.g., GTCS and TLE) by elevating extracellular K + and/or glutamate (Fig.  5 ). This implies that Kir4.1 channels serve as a novel therapeutic target for epilepsy, in that, such agents which enhance Kir4.1 channel function or which up-regulate Kir4.1 expression may become novel antiepileptic drugs. These agents seem to normalize the excess of extracellular K + caused by hyperexcitation of neurons and reduce the [Glu] o level under epileptic conditions. Since the action site (i.e., astrocytes) and mechanism (i.e., reduction of extracellular K + and glutamate) of the drugs acting on Kir4.1 channels are distinct from those of currently available antiepileptics (e.g., inhibition of Na + channels, Ca 2+ channels or GABA transaminase and stimulation of GABA A receptors), these agents are expected to produce additive (or synergistic) therapeutic actions even in combined treatment with current medications for epilepsy. In addition, it is now known that Kir4.1 channels are implicated in the pathogenesis not only of epilepsy, but also of multiple sclerosis and/or Huntington's disease [57, 58] . The ligand-based 3D-QSAR and docking simulation analyses on the Kir4.1 channel may provide important information for designing new drugs for the above CNS disorders in future drug discovery research [27] . Furthermore, since the inhibition of Kir4.1 channels is suggested to be involved in the pro-convulsive actions of CNS drugs, assessment of the blocking actions of new drug candidates for Kir4.1 channels may be important to avoid their pro-convulsive actions in drug discovery research.
Conclusions
Epilepsy is a serious neurological disorder and one third of patients with epilepsy are still refractory to current medications. Thus, the development of novel and more effective medicines or treatments for epilepsy is still a high unmet need to be addressed. Recent advances in research on the pathophysiological functions of Kir4.1 channels revealed that Kir4.1 can serve as a novel therapeutic target for epilepsy. Kir channels containing Kir4.1subunits are specifically expressed in astrocytes in the brain and mediate the spatial K + buffering function of astrocytes. Reduced expression or dysfunction of Kir4.1 channels evoked convulsive seizures both in animals and humans. Although the precise mechanisms remain to be clarified, dysfunction of Kir4.1 channels, especially in the amygdaloid nuclei, seems to be implicated in generating GTCS by elevating extracellular levels of K + and/or glutamate. Conversely, agents or treatments that activate Kir4.1 channels or up-regulate astroglial Kir4.1 expression may alleviate epileptic disorders. Docking simulation studies based on the Kir4.1 homology model allow for molecular design of new Kir4.1 ligands and analyses of Kir4.1-drug interaction. The development of new drugs or treatments which enhance Kir4.1 channel activity and astroglial K + buffering would improve current treatment options for epilepsy.
